Transarterial chemoembolization (TACE) is a standard treatment for intermediate-stage
hepatocellular carcinoma (HCC). In this review, we summarize recent updates on the use of …

Hepatocellular carcinoma (HCC) is the most common primary liver cancer, representing the
sixth leading cause of cancer and the third leading cause of cancer-related mortality. Patient …

Chronic infection with viral hepatitis affects half a billion individuals worldwide and can lead
to cirrhosis, cancer, and liver failure. Liver cancer is the third leading cause of cancer …

Precise nanomedicine has been extensively explored for efficient cancer imaging and
targeted cancer therapy, as evidenced by a few breakthroughs in their preclinical and …

Hepatocellular carcinoma (HCC) is the fifth most common cancer globally and the fourth
most common cancer in men in Korea, where the prevalence of chronic hepatitis B infection …

Abstract The Asia-Pacific Primary Liver Cancer Expert (APPLE) Consensus Statement on
the treatment strategy for patients with intermediate-stage hepatocellular carcinoma (HCC) …

We report on the long‐term intention‐to‐treat (ITT) outcome of 118 patients with
hepatocellular carcinoma (HCC) undergoing downstaging to within Milan/United Network for …

Hepatocellular carcinoma (HCC)—closely associated with liver cirrhosis and, in fact, the
main cause of death in patients with such disease—is now recognized as one of the most …

Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide. According
to the Barcelona Clinic Liver Cancer (BCLC) staging system, transarterial …

The intermediate stage of hepatocellular carcinoma (HCC) comprises a highly
heterogeneous patient population and therefore poses unique challenges for therapeutic …